a. Intramuscular cephalosporins
b. Intravenous vasopressors
c. Oral analgesics
d. Subcutaneous antiglycemics
ANS: C
c. Oral analgesics
When drugs are administered parenterally, there is no pharmaceutic phase, which occurs when a drug becomes a solution that can cross the biologic membrane.
a. Capsule
b. Enteric-coated pill
c. Liquid suspension
d. Tablet
ANS: C
c. Liquid suspension
Liquid drugs are already in solution, which is the form necessary for absorption in the GI tract. The other forms must disintegrate into small particles and then dissolve before being absorbed.
a. “I may crush the tablet and put it in applesauce to improve absorption.”
b. “I should consume acidic foods to enhance absorption of this medication.”
c. “I should expect a delay in onset of the drug’s effects after taking the tablet.”
d. “I should take this medication with high-fat foods to improve its action.”
ANS: C
c. “I should expect a delay in onset of the drug’s effects after taking the tablet.”
Enteric-coated tablets resist disintegration in the acidic environment of the stomach and disintegrate when they reach the small intestine. There is usually some delay in onset of actions after taking these medications. Enteric-coated tablets should not be crushed or chewed, which would alter the time and location of absorption. Acidic foods will not enhance the absorption of the medication. The patient should not to eat high-fat food before ingesting an enteric-coated tablet, because high-fat foods decrease the absorption rate.
a. absorption is diminished by the first-pass effects in the liver.
b. absorption is faster when insulin is given subcutaneously.
c. digestive enzymes in the gastrointestinal tract prevent absorption.
d. the oral form is less predictable with more adverse effects.
ANS: C
c. digestive enzymes in the gastrointestinal tract prevent absorption
Insulin, growth hormones, and other protein-based drugs are destroyed in the small intestine by digestive enzymes and must be given parenterally. Because insulin is destroyed by digestive enzymes, it would not make it to the liver for metabolism with a first-pass effect. Subcutaneous tissue has fewer blood vessels, so absorption is slower in such tissue. Insulin is given subcutaneously because it is desirable to have it absorb slowly.
a. must be taken on an empty stomach.
b. requires active transport for absorption.
c. should be taken with fatty foods.
d. will readily diffuse into the gastrointestinal tract.
ANS: B
b. requires active transport for absorption.
Water-soluble drugs require a carrier enzyme or protein to pass through the GI membrane.
a. On an empty stomach
b. With a full glass of water
c. With food
d. With high-fat food
ANS: C
c. With food
Food can stimulate the production of gastric acid so medications requiring an acidic environment should be given with a meal. High-fat foods are useful for drugs that are lipid soluble.
a. IM into the deltoid muscle
b. IM into the gluteal muscle
c. SubQ into abdominal tissue
d. SubQ into the upper arm
ANS: A
a. IM into the deltoid muscle
Drugs given IM are absorbed faster in muscles that have more blood vessels, such as the deltoid, rather than those with fewer blood vessels, such as the gluteals. Subcutaneous routes are used when absorption needs to be slower and more sustained.
a. “The first-pass effect means the drug may be absorbed into systemic circulation from the intestinal lumen.”
b. “The first-pass effect means the drug may be changed to an inactive form and excreted.”
c. “The first-pass effect means the drug may be changed to a metabolite, which may be more active than the original.”
d. “The first-pass effect means the drug may be unchanged as it passes through the liver.”
ANS: A
a. “The first-pass effect means the drug may be absorbed into systemic circulation from the intestinal lumen.”
Drugs that undergo first-pass metabolism are absorbed into the portal vein from the intestinal lumen and go through the liver where they are either unchanged or are metabolized to an inactive or a more active form.
a. bioavailability.
b. pinocytosis.
c. protein binding.
d. tachyphylaxis.
ANS: A
a. bioavailability.
Oral drugs may have less bioavailability because a lower percentage of the drug reaches the systemic circulation. Pinocytosis refers to the process by which cells carry a solute across a membrane. Protein binding can occur with both routes. Tachyphylaxis describes a rapid decrease in response to drugs that occurs when tolerance develops quickly.
a. decreased drug absorption.
b. decreased drug interactions.
c. decreased drug toxicity.
d. increased drug effects.
ANS: D
d. increased drug effects.
Drugs that are highly protein-bound bind with albumin and other proteins, leaving less free drug in circulation. If a patient has a low albumin, the drug is not bound, and there is more free drug to cause drug effects. There would be increased absorption, increased interactions with other drugs, and increased toxicity.
a. decreased bioavailability of both drugs.
b. decreased drug effects.
c. decreased drug interactions.
d. increased risk of adverse effects.
ANS: D
d. increased risk of adverse effects.
Two drugs that are highly protein-bound will compete for protein-binding sites, leaving more free drug in circulation and an increased risk of adverse effects as well as increased bioavailability, increased drug effects, and increased drug interactions.
a. decreased drug effects of the first drug.
b. decreased therapeutic range of the first drug.
c. increased drug effects of the first drug.
d. increased therapeutic range of the first drug.
ANS: C
c. increased drug effects of the first drug.
Adding another highly protein-bound drug will displace the first drug from protein-binding sites and release more free drug increasing the drug’s effects. This does not alter the therapeutic range, which is the serum level between drug effectiveness and toxicity
a. decreased drug effects.
b. increased drug effects.
c. decreased therapeutic range.
d. increased therapeutic range.
ANS: B
b. increased drug effects.
Liver diseases such as cirrhosis and hepatitis alter drug metabolism by inhibiting the drug-metabolizing enzymes in the liver. When the drug metabolism rate is decreased, excess drug accumulation can occur and lead to toxicity.
a. None
b. 50 mg
c. 100 mg
d. 200 mg
ANS: C
c. 100 mg
Eight hours after the drug is given, there will be 400 mg left. Eight hours after that (16 hours), there will be 200 mg left. At 24 hours, there will be 100 mg left.
a. 0800 on Tuesday
b. 0800 on Wednesday
c. 0800 on Thursday
d. 0800 on Friday
ANS: B
b. 0800 on Wednesday
Steady-state levels occur at 3 to 5 half-lives. Wednesday at 0800 is 4 half-lives from the original dose.
a. Administer the medication as ordered.
b. Contact the provider to discuss daily dosing.
c. Discuss every-other-day dosing with the provider.
d. Hold the medication and notify the provider.
ANS: B
b. Contact the provider to discuss daily dosing.
A drug with a longer half-life should be given at longer intervals to avoid drug toxicity.
a. To counter the toxic effects of the aspirin
b. To decrease the half-life of the aspirin
c. To increase the excretion of the aspirin
d. To neutralize the acid of the aspirin
ANS: C
c. To increase the excretion of the aspirin
Aspirin is a weak acid and is more readily excreted in alkaline urine. Sodium bicarbonate alkalizes the urine. It does not act as an antidote to aspirin, decrease the half-life, or neutralize its pH.
a. Administer the drug as ordered.
b. Anticipate a shorter than usual half-life of the drug.
c. Expect decreased drug effects when the drug is given.
d. Notify the provider and discuss giving a lower dose.
ANS: D
d. Notify the provider and discuss giving a lower dose.
Increased creatinine and BUN indicate decreased renal function so a drug that is eliminated through the kidneys can become toxic. The nurse should discuss a lower dose with the provider. The drug will have a longer half-life and will exhibit increased effects with decreased renal function.
a. duration of action.
b. onset of action.
c. peak action time.
d. time response curve.
ANS: B
b. onset of action.
The onset of action is the time it takes to reach the MEC. Duration of action is the length of time a drug has a pharmacologic effect. Peak action time occurs when the drug reaches its highest blood level. The time response curve is an evaluation of the other three measures.
a. agonist.
b. antagonist.
c. inhibitor.
d. depressant.
ANS: A
a. agonist.
An agonist medication is one that stimulates a certain type of cell to produce a response.
a. “Nonspecific drugs can affect specific receptor types in different body tissues.”
b. “Nonspecific drugs can affect a variety of receptor types in similar body tissues.”
c. “Nonspecific drugs can affect hormone secretion as well as cellular functions.”
d. “Nonspecific drugs require higher doses than specific drugs to be effective.”
ANS: D
d. “Nonspecific drugs require higher doses than specific drugs to be effective.”
Nonspecific drugs can act on one type of receptor but in different body tissues, or a variety of receptor types, or act on hormones to produce effects. Nonspecific drugs do not require higher doses.
a. Administer the drug as ordered.
b. Administer the drug and monitor for adverse effects.
c. Notify the provider to discuss decreasing the dose.
d. Notify the provider to report a toxic drug level.
ANS: D
d. Notify the provider to report a toxic drug level.
The trough drug level for gentamicin should be less than 2 mcg/mL. The nurse should not administer the drug and should notify the provider of the toxic level.
a. Administer the dose as ordered.
b. Give the dose and monitor for toxicity.
c. Hold the dose until reviewing it with the provider.
d. Refuse to give the dose.
ANS: A
a. Administer the dose as ordered.
Digoxin requires a loading dose when first prescribed.
a. drug-seeking behavior.
b. drug tolerance.
c. the placebo effect.
d. tachyphylaxis.
ANS: D
d. tachyphylaxis.
Tachyphylaxis is a rapid decrease in response, or acute tolerance. Tolerance to drug effects can occur with narcotics, requiring increased doses in order to achieve adequate drug effects. Nurses often mistake drug-seeking behavior for drug tolerance. The placebo effect occurs when the patient experiences a response with an inactive drug.